Pan, 762 patient aspirin prophylaxis study: 13% higher mortality [p=0.63] and 2% higher combined mortality/intubation [p=0.93] https://c19p.org/pan
copied to clipboard
Pre-hospital antiplatelet medication use on COVID-19 disease severity
et al., Heart & Lung, doi:10.1016/j.hrtlng.2021.04.010
Retrospective 762 COVID+ hospitalized patients in the USA, 239 on antiplatelet medication (199 aspirin), showing no significant differences in outcomes.
|
risk of death, 13.0% higher, OR 1.13, p = 0.63, treatment 239, control 523, adjusted per study, MOS 6 vs. <6, multivariable, RR approximated with OR.
|
|
risk of death/intubation, 2.0% higher, OR 1.02, p = 0.93, treatment 239, control 523, adjusted per study, MOS 5+ vs. <5, multivariable, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Pan et al., 5/26/2021, retrospective, USA, North America, peer-reviewed, 11 authors, study period 1 March, 2020 - 9 April, 2020.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.